- Q3 2026 revenue $24.4B, +39% YoY
- Adj. EPS $7.48, +7% YoY
- Mounjaro revenue $10.7B, +65% YoY
Revenue $24.4B vs est. $22.61B. Adj. EPS $7.48 vs est. $5.59. Mounjaro revenue $10.7B. FY26 revenue guidance raised to $91B-$92B from $85B-$87B. EPS guidance narrowed to $35-$36 from $35.50-$36.50. Includes $4.57/share IPR&D charges.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.